You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

185 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Dec 2024
Drug
Other Name(s): Camptosar®
Apr 2023
Drug
Other Name(s): Sarclisa®
Mar 2024
Le test de dépistage du cancer du col de l’utérus recherche les types de virus du papillome humain (VPH) qui peuvent parfois provoquer un cancer du...
The resources in this toolkit will help radiologists and other imaging professionals provide consistent and high-quality imaging according to best...
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - In Combination with Rituximab for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
Apr 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
May 2025

Pages